Does the media refer more to EYPT or LBRX?

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Eyepoint Pharmaceuticals' score of 0.33 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer EYPT or HROW?

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than Harrow. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 1 mentions for Harrow. Eyepoint Pharmaceuticals' average media sentiment score of 0.33 beat Harrow's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EYPT or CRON?

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Cronos Group. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.99 beat Eyepoint Pharmaceuticals' score of 0.33 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EYPT or ANRO?

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 3 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.70 beat Eyepoint Pharmaceuticals' score of 0.33 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EYPT or CALT?

Eyepoint Pharmaceuticals presently has a consensus target price of $25.70, indicating a potential upside of 590.86%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyepoint Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Eyepoint Pharmaceuticals (EYPT) Competitors

$3.72 -0.35 (-8.60%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.72 0.00 (0.00%)

As of 06:07 AM Eastern

Compare

EYPT vs. LBRX, HROW, CRON, ANRO, and CALT

Should you buy Eyepoint Pharmaceuticals stock or one of its competitors? Eyepoint Pharmaceuticals's main competitors and comparable companies include LB Pharmaceuticals (LBRX), Harrow (HROW), Cronos Group (CRON), Alto Neuroscience (ANRO), and Calliditas Therapeutics AB (publ) (CALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eyepoint Pharmaceuticals compare to LB Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

LB Pharmaceuticals has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. LB Pharmaceuticals' return on equity of -25.92% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LB Pharmaceuticals has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	10.22	-$231.96M	-$3.74	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, indicating a potential upside of 590.86%. LB Pharmaceuticals has a consensus price target of $49.63, indicating a potential upside of 26.63%. Given Eyepoint Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Eyepoint Pharmaceuticals' score of 0.33 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

LB Pharmaceuticals beats Eyepoint Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Harrow?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Harrow (NASDAQ:HROW) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Harrow has a net margin of -13.51% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Harrow's return on equity of -38.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Harrow	-13.51%	-38.00%	-3.37%

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eyepoint Pharmaceuticals has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Harrow has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Eyepoint Pharmaceuticals currently has a consensus price target of $25.70, indicating a potential upside of 590.86%. Harrow has a consensus price target of $66.71, indicating a potential upside of 98.55%. Given Eyepoint Pharmaceuticals' higher possible upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Harrow has higher revenue and earnings than Eyepoint Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	10.22	-$231.96M	-$3.74	N/A
Harrow	$275.59M	4.57	-$5.14M	-$1.00	N/A

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than Harrow. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 1 mentions for Harrow. Eyepoint Pharmaceuticals' average media sentiment score of 0.33 beat Harrow's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Harrow beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Cronos Group?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Eyepoint Pharmaceuticals has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Cronos Group has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	10.22	-$231.96M	-$3.74	N/A
Cronos Group	$179.09M	7.00	-$9.45M	$0.20	17.00

Eyepoint Pharmaceuticals presently has a consensus target price of $25.70, indicating a potential upside of 590.86%. Cronos Group has a consensus target price of $2.30, indicating a potential downside of 32.35%. Given Eyepoint Pharmaceuticals' higher possible upside, equities research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Cronos Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Cronos Group. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.99 beat Eyepoint Pharmaceuticals' score of 0.33 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cronos Group	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cronos Group has a net margin of 39.08% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Cronos Group's return on equity of 4.85% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Cronos Group	39.08%	4.85%	4.62%

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 7.8% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cronos Group beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Eyepoint Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, suggesting a potential upside of 590.86%. Alto Neuroscience has a consensus price target of $37.25, suggesting a potential upside of 35.55%. Given Eyepoint Pharmaceuticals' higher probable upside, equities research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 3 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.70 beat Eyepoint Pharmaceuticals' score of 0.33 indicating that Alto Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alto Neuroscience	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alto Neuroscience has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Alto Neuroscience is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	10.22	-$231.96M	-$3.74	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alto Neuroscience has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Alto Neuroscience's return on equity of -46.46% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Alto Neuroscience	N/A	-46.46%	-39.09%

Summary

Alto Neuroscience beats Eyepoint Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Eyepoint Pharmaceuticals has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Eyepoint Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	10.22	-$231.96M	-$3.74	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

In the previous week, Eyepoint Pharmaceuticals had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Eyepoint Pharmaceuticals' average media sentiment score of 0.33 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Eyepoint Pharmaceuticals presently has a consensus target price of $25.70, indicating a potential upside of 590.86%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Summary

Eyepoint Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EYPT vs. The Competition

Export

Metric	Eyepoint Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$350.88M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.99	792.28	274.08	25.69
Price / Sales	10.22	862.22	638.21	78.99
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.01	10.59	10.47	6.32
Net Income	-$231.96M	$2.81B	$3.49B	$359.73M
7 Day Performance	-6.77%	-0.11%	-0.67%	0.17%
1 Month Performance	-23.61%	-1.34%	-3.17%	-3.27%
1 Year Performance	-73.58%	2.86%	15.14%	5.58%

Eyepoint Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EYPT Eyepoint Pharmaceuticals	3.2397 of 5 stars	$3.72 -8.6%	$25.70 +590.9%	-72.2%	$350.88M	$31.37M	N/A	214
LBRX LB Pharmaceuticals	2.6628 of 5 stars	$42.24 -1.7%	$49.63 +17.5%	+163.0%	$1.36B	N/A	N/A	27	Positive News
HROW Harrow	1.7223 of 5 stars	$34.49 +1.7%	$66.38 +92.5%	-31.2%	$1.29B	$272.30M	N/A	373
CRON Cronos Group	1.5778 of 5 stars	$3.44 +3.2%	$2.30 -33.0%	+28.8%	$1.27B	$146.59M	17.18	610
ANRO Alto Neuroscience	2.2323 of 5 stars	$30.57 -0.2%	$37.25 +21.9%	+571.7%	$1.20B	N/A	N/A	68

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. LBRX, HROW, CRON, ANRO, and CALT

How does Eyepoint Pharmaceuticals compare to LB Pharmaceuticals?

Summary

How does Eyepoint Pharmaceuticals compare to Harrow?

Summary

How does Eyepoint Pharmaceuticals compare to Cronos Group?

Summary

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Summary

How does Eyepoint Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. LBRX, HROW, CRON, ANRO, and CALT

How does Eyepoint Pharmaceuticals compare to LB Pharmaceuticals?

Is EYPT or LBRX more profitable?

Do insiders and institutionals believe in EYPT or LBRX?

Which has preferable earnings and valuation, EYPT or LBRX?

Do analysts rate EYPT or LBRX?

Does the media refer more to EYPT or LBRX?

Summary

How does Eyepoint Pharmaceuticals compare to Harrow?

Is EYPT or HROW more profitable?

Do institutionals & insiders believe in EYPT or HROW?

Which has more risk and volatility, EYPT or HROW?

Do analysts recommend EYPT or HROW?

Which has stronger valuation & earnings, EYPT or HROW?

Does the media prefer EYPT or HROW?

Summary

How does Eyepoint Pharmaceuticals compare to Cronos Group?

Which has more volatility and risk, EYPT or CRON?

Which has better earnings and valuation, EYPT or CRON?

Do analysts prefer EYPT or CRON?

Does the media prefer EYPT or CRON?

Is EYPT or CRON more profitable?

Do institutionals and insiders believe in EYPT or CRON?

Summary

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Which has more volatility and risk, EYPT or ANRO?

Do analysts rate EYPT or ANRO?

Does the media prefer EYPT or ANRO?

Which has better valuation & earnings, EYPT or ANRO?

Do institutionals & insiders hold more shares of EYPT or ANRO?

Is EYPT or ANRO more profitable?

Summary

How does Eyepoint Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Which has more risk and volatility, EYPT or CALT?

Do insiders & institutionals believe in EYPT or CALT?

Which has preferable earnings & valuation, EYPT or CALT?

Does the media favor EYPT or CALT?

Do analysts prefer EYPT or CALT?

Is EYPT or CALT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools